Psychedelics as a Treatment for Alzheimer’s Disease Dementia, Simon Andrew Vann Jones and Allison O’Kelly, 2020

Psychedelics as a Treatment for Alzheimer’s Disease Dementia

Simon Andrew Vann Jones and Allison O’Kelly

Cornwall Partnership NHS Foundation Trust, Liskeard, United Kingdom

Frontiers in Synaptic Neuroscience, August 2020 | Volume 12 | Article 34

doi : 10.3389/fnsyn.2020.00034


Currently, there are no disease-modifying treatments for Alzheimer’s disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions due to their potential to stimulate neurogenesis, provoke neuroplastic changes and reduce neuroinflammation. This inevitably makes them interesting candidates for therapeutics in dementia. This mini-review will look at the basic science and current clinical evidence for the role of psychedelics in treating dementia, especially early AD, with a particular focus on microdosing of the classical psychedelics LSD and psilocybin.

Keywords : psychedelic, Alzheimer’s disease, dementia, plasticicity, microdosing



Globally an estimated 50 million people have a diagnosis of dementia and population prevalence continues to increase (Alzheimer’s Society, 2019; UK Government Web Archive, 2020). Alzheimer’s disease (AD) accounts for approximately 50–70% of cases (Draper, 2013). AD is a progressive neurological disorder characterized by extracellular amyloid protein deposition and intracellular tau protein aggregates (tangles) that, in accumulation, are associated with a variety of pathological processes including microtubular damage, axonal transport disruption and, ultimately, cell death. The hippocampus, a key structure in the ability to learn and retain information and a site for neurogenesis, is particularly vulnerable to AD pathology and one of the earliest parts of the brain to be affected by the disease (Mu and Gage, 2011; Pilly and Grossberg, 2012; Setti et al., 2017).

Currently, there is a renaissance of research using psychedelics, potent 5HT2A receptor (5HT2A-R) agonists, in psychiatric and neurological disorders (Nichols, 2004; Halberstadt, 2015; Aday et al., 2020). The 5HT2A-R is found in high concentrations in regions of the brain vulnerable to dementia such as the prefrontal cortex and aforementioned hippocampus (Wood et al., 2012; Catlow et al., 2013; Bryson et al., 2017). Psychedelics induce brain plasticity and modify connectivity between brain regions and there is considerable anecdotal evidence of cognitive benefits from micro-dosing—a dose that does not cause perceptual change or impair functioning (Carhart-Harris et al., 2012; Wood et al., 2012; Catlow et al., 2013; Muthukumaraswamy et al., 2013; Zhang and Stackman, 2015; Griffiths et al., 2016; Carhart-Harris and Goodwin, 2017a; Carhart-Harris and Nutt, 2017; Johnstad, 2018; Fadiman and Korb, 2019; Kuypers et al., 2019; Lea et al., 2020a).


High dose psilocybin reduces attention to both clinical and electrophysiological parameters. However, this may be due to an increased awareness of sensory stimuli that are usually filtered out (cost of attention) rather than reduced attentional ability per se (Carter et al., 2005; Bravermanová et al., 2018). In younger adults, the only controlled studies of microdosing LSD to date (n = 20 and n = 24, respectively), both using a within-subjects design, found no effects either positive or negative on the cognitive function of healthy volunteers at different sub-perceptual doses (Bershad et al., 2019; Hutten et al., 2020). Participants had all previously experienced psychedelics.

The former study used a placebo, 6.5, 13, and 26 mg, and the latter study placebo, 5, 10, or 20 mg. In the latter study, subjects had objective increases in psychomotor vigilance (and subjective happiness and mood scores) coupled with a paradoxical reduction in concentration and reduced set-shifting ability at the highest microdose (20 mg) hours after ingestion.

Participants also reported subjectively greater productivity at 10 micrograms and no discernible subjective or objective differences at five micrograms compared to placebo (Hutten et al., 2020). Importantly, subjects were aware that they were on the active drug at the two higher doses and had the experience of recreational drug use.

A 2018 uncontrolled, open-label naturalistic trial found increased cognitive fluency, flexibility, and originality amongst the 33 participants at various micro-doses of psilocybin (Prochazkova et al., 2018). However, results should be interpreted with a degree of caution due to the risk of selection bias (the study was organized by the Dutch Psychedelic Society), a lack of a placebo control arm, risk of practice effect bias, and no intention-to-treat analysis.

In older adults, a recent double-blind placebo-controlled study in older adults (n = 48) who had not taken LSD for at least the past 5 years found no difference in the number of adverse events (including cognitive impairment) between those taking placebo, 5, 10, or 20 mg doses every 5 days for 28 days (Family  et al., 2020). Headaches were reported more often in those taking LSD however the small number of participants and non-linear dose-response makes this difficult to interpret. In general, the medication was well tolerated with no serious adverse events or drop-outs.


In rat models, 5HT2A-R activation with mid-dose psilocybin (0.13 mg/kg) enhances both prospective and retrospective learning with lesser effects at low-dose (0.06 mg/kg; Buchborn et al., 2014; Cini et al., 2019). Consecutive daily dosing diminished benefits, and older rodents learning was enhanced by an enriched environment (Buchborn et al., 2014).

An observational study of 89 recreational users micro-dosing psychedelics found self-reported improvement across multiple psychological domains, including creativity and attention, with a sustained improvement over 6 weeks (Polito and Stevenson, 2019). Studies of recreational micro-dosing, highly vulnerable to bias but arguably self-selecting for longer-term users, report improvement in cognitive focus and attention (14–61% of users; Anderson et al., 2019; Hutten et al., 2019; Lea et al., 2020b). However only one of these studies reported figures for the duration of use, with 60.5% of respondents using for 3 months of more (Lea et al., 2020b).

There have been no properly controlled studies of microdosing in cognitively impaired humans or effects on cognition or mood beyond the acute phase. However, studies of high dose LSD and psilocybin have shown long-term benefits on mood.

A study of 16 healthy subjects showed subjective benefits of a single dose of 200 mg LSD 12 months later, with 10 participants rating the experience as one of the top 10 most meaningful of their lives (Schmid and Liechti, 2018). In 10 patients with a life-threatening disease, LSD-assisted psychotherapy reduced anxiety significantly, an effect that persisted 12-months after therapy in 77.7%. Two-thirds of the respondents also reported that the experience has improved their quality of life (Gasser et al., 2015). Similar results have been observed following high dose psilocybin both in patients with anxiety related to life-threatening cancer, and cancer-related depression and anxiety (n = 51 and 29 respectively, both cross-over design; Griffiths et al., 2016; Ross et al., 2016). Both studies reported that approximately 60–80% of participants had a clinically significant response that was sustained some 6 months later. The latter study also followed up 4.5 years later and found that these results were sustained, with 71–100% of participants reporting the experience being one of the most meaningful of their lives (Agin-Liebes et al., 2020).

In treatment-resistant depression, 10 mg and 25 mg of psilocybin given 1 week apart (n = 20), led to clinical response or remission in 14 participants sustained at assessment 5 weeks later. This effect persisted at 6 months follow up despite no further treatment (Carhart-Harris et al., 2018). These encouraging results have led, in part, to approval for a trial of high-dose psilocybin specifically targeting depression in early AD (, 2020).


Specific 5HT2A-R polymorphisms impair verbal memory recall and object recognition and reduced 5HT2A-R density in areas of the brain responsible for key memory processes are associated with worse cognitive performance (Schott et al., 2011). Pre-task 5HT2A-R activation in mice enhances post-task hippocampal long-term potentiation and enables the re-consolidation of fear conditioning in the amygdala supporting a critical role in neuroplasticity (Catlow et al., 2013; Zhang et al., 2013). This effect can be reproduced in rats and rabbits by very low dose psychedelics but is abolished by higher doses (Romano et al., 2010; Cameron et al., 2019).

In rats, 5HT2A-R activation stimulates neurogenesis and brain-derived neurotrophic factor (BDNF) expression in the neocortex but appears to consistently inhibit the same process in the hippocampus (Vaidya et al., 1997). This may be dosedependent, with higher doses suppressing neurogenesis beyond a certain threshold. In cultured rat neurons, activation also stimulates dendritic spine proliferation and growth (Jones et al., 2009; Yoshida et al., 2011). In a mouse model of fear conditioning, both low and high dose psilocybin led to complete resolution of a cued fear response in animals that had been primed for a shock by an auditory tone (Catlow et al., 2013). This process was more rapid at lower doses where hippocampal neurogenesis was unimpaired. In rat cortical neuron cultures and drosophila larvae, LSD promotes neurogenesis and synaptogenesis in a dose-dependent manner suggesting both an important cross-species evolutionary pathway for this effect and that there may be an optimal dose to which it may be therapeutic for this purpose (Ly et al., 2018).

There is also likely to be an optimal dose spacing. Repeated administration of LSD and/or psilocybin leads to rapid tolerance, or tachyphylaxis, of mental effects from 24 h which peaks after just four consecutive daily doses, cannot be overcome even with substantial dose increases or switching to the other substance (cross-tolerance) and is completely reversed by 5 days of abstinence (Buchborn et al., 2016). In rats, high doses of LSD (0.16 mg/kg) given every 2 days for 90 days resulted in hyperactive and asocial symptoms (Martin et al., 2014). The aforementioned double-blind placebo-controlled safety study in older adults using a schedule of a dose every fourth day (Family et al., 2020). This may be optimal as tachyphylaxis is unlikely at this infrequency and, importantly, side effects were minimal and not significantly different to those on placebo.


Human gamma frequency oscillations (30–100 Hz) within neuronal networks are important for communication between brain regions, particularly those involving attention and memory (Jensen et al., 2007; Verret et al., 2012; Mably and Colgin, 2018). These networks become disrupted decades before the onset of symptoms in AD, possibly linked to dysfunctional inhibitory interneurons leading to the disruption of the gammamediated temporal structure for cortical processing which allows for the coherent packaging of sensory information (Weber and Andrade, 2010; Palop and Mucke, 2016). Studies in mild cognitive impairment and AD show contradictory results on levels of gamma activity with some showing an increase and others a decrease in vulnerable brain regions and networks (Wang et al., 2017). Error! Bookmark not defined (König et al., 2005; Van Deursen et al., 2008; Basar et al., 2017). However, a recent study found that gamma frequency response is slowed in response to stimulus in Alzheimer patients suggesting that the increase in gamma power seen in some studies with AD patients may the greater use of brain resources to maintain resting state (Basar et al., 2016). The same researchers found that long-distance gamma-related connectivity was heightened in AD patients compared to controls (Basar et al., 2017). It is possible that this increase in gamma activity is an initial response to brain failure but that this process is fatigable.

In recent studies, enhancing gamma frequency oscillations via external stimuli reduced amyloid burden, possibly via increased microglia activity, and improved cognitive function in rodents (Laccarino et al., 2016; Martorell et al., 2019). 5HT2A-R agonists enhance the power of gamma-frequency recordings suggesting a role for the 5HT2A-R both in mediating long-range projections and reducing focal Alzheimer’s pathology (Puig et al., 2010; Athilingam et al., 2017).